Endogenous Opioid Peptides Contribute to Antinociceptive Potency of Intrathecal [Dmt1]DALDA
Authors:
- Hazel H. SzetoHSHazel H. Szeto
- Yi SoongYSYi Soong
- Dunli WuDWDunli Wu
- XuanXuan QianXQXuanXuan Qian
- Guo-Min ZhaoGZGuo-Min Zhao
- 1 May 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (2) , 696-702
Abstract
[Dmt1]DALDA (H-Dmt-d-Arg-Phe-Lys-NH2; Dmt = 2′,6′-dimethyltyrosine) is a dermorphin analog that shows high affinity and selectivity for the μ opioid receptor. The intrathecal potency of [Dmt1]DALDA far exceeded its affinity at μ receptors and suggests that other mechanisms must be involved in its action in the spinal cord. The affinity and selectivity of [Dmt1]DALDA was determined using cell membranes expressing cloned human μ, δ, and κ opioid receptors. Competitive displacement binding with [3H][Dmt1]DALDA, [3H]DPDPE (H-Tyr-d-Pen-Gly-Phe-d-Pen), and [3H]U69,593 [(5α,7α,8β)-(+)-N-methyl-N-(7-[1-pyrrolidinyl]-1-oxaspiro[4.5]dec-8-yl)-benzeneacetamide] revealed Ki of 156 ± 26 pM for μ opioid receptor (MOR), 1.67 ± 0.04 μM for δ opioid receptor (DOR), and Ki of 4.4 ± 1.7 nM for κ opioid receptor (KOR), respectively. [Dmt1]DALDA increased guanosine 5′-O-(3-[35S]thiotriphosphate) binding in MOR, DOR, and KOR membranes, with EC50 being 17 (8.8–33) nM, 2 (1.2–3.2) μM, and 124 (15–1000) nM, respectively. Intrathecal [Dmt1]DALDA inhibited the tail-flick response in mice with ED50 = 1.22 (0.59–2.34) pmol. Intrathecal administration of an antiserum against dynorphin A(1-17) or [Met5]enkephalin significantly attenuated the response to i.t. [Dmt1]DALDA, resulting in ED50 of 6.2 (3.6–12.6) pmol and 6.6 (3.5–19.6) pmol, respectively. Neither antisera had any effect on the response to i.t. morphine. Intracerebroventricular (i.c.v.) [Dmt1]DALDA was not affected by previous i.c.v. administration of anti-Dyn or anti-ME. Pretreatment with norbinaltorphimine or naltriben also attenuated the antinociceptive response to i.t., but not i.c.v., [Dmt1]DALDA. These data suggest that i.t. [Dmt1]DALDA causes the release of dynorphin and [Met5]enkephalin-like substances that act at κ and δ receptors, respectively, to contribute to the extraordinary potency of [Dmt1]DALDA.Keywords
This publication has 29 references indexed in Scilit:
- Profound Spinal Tolerance after Repeated Exposure to a Highly Selective μ-Opioid Peptide Agonist: Role of δ-Opioid ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- DREAM Is a Critical Transcriptional Repressor for Pain ModulationCell, 2002
- Differential involvement of μ-opioid receptor subtypes in endomorphin-1- and -2-induced antinociceptionEuropean Journal of Pharmacology, 1999
- A potent and selective endogenous agonist for the µ-opiate receptorNature, 1997
- Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxonePain, 1996
- Enkephalin antinociception in mice is mediated by δ1- and δ2-opioid receptors in the brain and spinal cord, respectivelyEuropean Journal of Pharmacology, 1993
- N-methyl-d-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: behavioral and histological studiesBrain Research, 1992
- Dermorphin analogs carrying an increased positive net charge in their "message" domain display extremely high .mu.-opioid receptor selectivityJournal of Medicinal Chemistry, 1989
- Autoradiographic distribution of Mu1 and Mu2 opioid binding in the mouse central nervous systemBrain Research, 1985
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973